Race oncology top 20 shareholders
WebOct 17, 2024 · Race Oncology's cash burn of AU$6.3m is about 1.7% of its AU$373m market capitalisation. So it could almost certainly just borrow a little to fund another year's growth, or else easily raise the ... WebHere you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology. ASX Announcements. Reports. Title Link; Annual Report 2024: Download: Race Oncology - Pitt Street Research Initiation Report - …
Race oncology top 20 shareholders
Did you know?
WebRace Oncology Targeting Zantrene® towards better cancer outcomes. Contact Us. Visit. L36, 1 Macquarie Place, Sydney, NSW, 2000. Email. [email protected]. Phone +61 2 … WebApr 7, 2024 · 8.4%. 10% most volatile stocks in AU Market. 14.9%. 10% least volatile stocks in AU Market. 3.5%. Stable Share Price: RAC is not significantly more volatile than the rest …
WebMar 22, 2024 · Merck & Co. Inc.'s blockbuster Keytruda led the oncology race with $14.38 billion in revenue, a 29.7% increase from 2024, followed by Bristol-Myers Squibb Co.'s Revlimid with $12.11 billion. Bristol Myers' Opdivo was one of the rare cancer drugs for which revenue fell in 2024, down 2.9% to $6.99 billion. WebOct 23, 2024 · Insider Ownership. Insiders form another group of important ownership types as they manage the company’s operations and decide the best use of capital. Insider …
WebAug 20, 2024 · A half-million dollar investment in cancer fighter Race Oncology (ASX:RAC) from Australian biotech entrepreneur Dr Daniel Tillett has pushed shares in the company … WebRace Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com . Top 20 Holders Race is please to share the current Top 20 shareholders as of 30 September 2024. Shareholders can expect regular updates in future quarterly reports. Position Holder Name Holding IC
WebDr Tillett is the CEO and founder of Nucleics Pty Ltd, a private biotechnology company in the genomics space. He was previously a Senior Lecturer within the School of Pharmacy at La …
WebRace Oncology Limited (ASX: RAC) is pleased to announce that it has received binding commitments to raise $5.4m (before associated costs) in an oversubscribed equity … god bless heroWebRace Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Zantrene. Home. About. Zantrene ® is a potent small molecule inhibitor of the … bon mardionWebAll the latest Race Oncology Limited (ASX:RAC) share price movements, ... Guess which All Ordinaries stock is soaring over 20% today. ... Top Shareholders Data provided by … bonmario incWebDecember 2024 Update. Race is pleased to announce the appointment of global pharmaceutical and commercial leader, Mr Damian Clarke-Bruce, as Managing Director … bon mariobon mardi images facebookWebHe was also a former Director of Race Oncology, the Australian company Garner made a boatload of cash from. Chris Ntoumenopoulos serves as a Director of Tryp Therapeutics: Chris is a Managing Director at 21 Corporate, an Australian-based corporate advisory firm, and is an entrepreneur searching the world for disruptive technologies and companies. god bless him shirtWebbusiness was sold to Morningstar) has operated independently from Aegis by former Aegis senior executives/shareholders to provide clients with unparalleled research that covers … bon maree